Merck Serono announces Global Grants Program to fund scientific innovation

Merck KGaAMerck Serono, the biopharmaceutical division of Merck, has announced the launch of Merck Global Grants - a program that underscores the company's commitment to funding scientific innovation and independent medical education around the world. The initiative encompasses Merck Serono's complete grants portfolio, including the Grants for Innovation in Research and Grants for Independent Medical Education.

The program totals an annual investment of €20 million across all grants programs, highlighting the company's efforts to promote advances in the field of medicine, addressing recognized gaps in healthcare knowledge, and improving the quality of patient care.

"Merck Serono has a long-standing reputation as a strong advocate for scientific innovation and medical education, believing that both are integral to helping healthcare professionals bring enhanced care to patients," said Steven Hildemann, Global Chief Medical Officer and Head of Global Medical and Safety at Merck Serono.

The Grants for Innovation in Research identify and fund promising research from across biopharma, including academia, research centers, smaller start-ups and independent researchers. Specific grants focus on areas in which Merck Serono has a strong R&D and commercial presence, including the Grant for Oncology Innovation, Grant for Multiple Sclerosis Innovation, Grant for Fertility Innovation, and Grant for Growth Innovation.

The Grants for Independent Medical Education foster the advancement of medicine, and address recognized gaps in healthcare knowledge, in order to improve patient care. The program includes the launch of an online portal which allows highly transparent and ethical interactions with medical education providers and represents an important milestone in the Merck Serono Medical Education Strategy. Funding is provided to educational institutions such as universities, medical education providers, medical scientists and scientific organizations.

To review eligibility requirements or apply for a grant, visit:
http://www.merck-grants.com

About Merck Serono
Merck Serono is the biopharmaceutical division of Merck. With headquarters in Darmstadt, Germany, Merck Serono offers leading brands in 150 countries to help patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono.

Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of neurology, oncology, immuno-oncology and immunology.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...